Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC By Ogkologos - August 21, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-426 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR “After a fire and a pandemic, it felt amazing to finish... November 1, 2021 Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why January 27, 2022 Cancer Control in American Indian and Alaska Native Populations: A Conversation... April 25, 2018 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,... May 19, 2021 Load more HOT NEWS The stories behind Teenage and Young Adult Cancer Awareness Month Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus... Study Shows Music Eases Pain and Other Symptoms for Patients Undergoing... ctDNA-Guided Treatment Influence on Survival in Advanced NSCLC
